Whalesbook
Record Revenue, Profit Slide Fuels Stock Rally
Epigral shares climbed more than 10% after the company announced record quarterly revenue of ₹736 crore. However, the strong sales growth was accompanied by a 6.84% drop in net profit and a 4.96% decline in EBITDA year-over-year, indicating that margin pressures are affecting profitability even as sales volumes increase.
Expansion Investments vs. Valuation Discount
Epigral's revenue reached ₹736.16 crore in Q4 FY26, up 17.29% from the prior year, driven by strong demand and a return to normal operations after maintenance. Yet, net profit fell to ₹80.95 crore from ₹86.89 crore, and EBITDA contracted 4.96% to ₹168.01 crore. This decline suggests rising costs, possibly for raw materials in its CPVC segment, are squeezing margins.
Epigral is heavily investing in future growth, spending ₹394 crore on capacity expansions in FY26. This includes boosting CPVC resin capacity to 150,000 TPA and epichlorohydrin to 100,000 TPA, alongside increasing its renewable energy output. Despite ambitious plans and a strong Return on Equity (ROE) of 24.93%, Epigral trades at a significant discount. Its Trailing Twelve Month (TTM) Price-to-Earnings (P/E) ratio of about 15.5x is much lower than peers like Clean Science (~35.66x) and Alkyl Amines (~42.80x), and the sector average of 30x-42x. This valuation gap suggests investors are wary about the long-term sustainability of its profit margins. The company maintains solid finances with a debt-to-equity ratio of about 0.31.
Sector Pressures and Future Demand
The stock's rally, despite falling profits, highlights investor focus on potential future growth over current margin challenges. The wider chemical industry faces external pressures, such as fluctuating oil prices and geopolitical issues, which can increase raw material and energy costs for companies like Epigral. While management points to strong demand, these global economic factors add a layer of uncertainty that may explain the significant valuation discount compared to competitors.
Analyst Confidence in Growth
Management expects current demand trends to continue into FY27 if global economic conditions remain stable. Analysts largely agree, maintaining a "Strong Buy" consensus and an average 12-month price target of ₹2,000. This positive outlook suggests that the market believes Epigral's expansion plans will drive future value, outweighing the current concerns about profit margins.